$1.51 Billion is the total value of Frazier Life Sciences Management, L.P.'s 52 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCKT | New | ROCKET PHARMACEUTICALS INC | $28,747,736 | – | 1,403,013 | +100.0% | 1.91% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $23,358,196 | – | 614,043 | +100.0% | 1.55% | – |
| New | AN2 THERAPEUTICS INC | $22,333,335 | – | 1,388,889 | +100.0% | 1.48% | – | |
| SVRA | New | SAVARA INC | $15,120,000 | – | 4,000,000 | +100.0% | 1.00% | – |
| New | SOLENO THERAPEUTICS INC | $13,720,291 | – | 464,937 | +100.0% | 0.91% | – | |
| New | APOGEE THERAPEUTICS INC | $8,520,000 | – | 400,000 | +100.0% | 0.57% | – | |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $7,227,050 | – | 292,002 | +100.0% | 0.48% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INCput | $1,566,000 | – | 600,000 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.